Other content tagged: anti-VEGF

One- and two-year follow-up outcomes of the CARE-ROP study

The CARE-ROP study identified ranibizumab as an effective treatment to control acute retinopathy of prematurity (ROP), an eye disease that affects preterm babies. For 16 preterm children entering the follow-up period, their ophthalmologic- and neurodevelopment was assessed at the one-year and two-year visits post-baseline. The patients’ outcomes of ranibizumab usage are very reassuring regarding long-term safety. Yet, late reactivation of ROP can represent a challenge and calls for regular follow-ups. Retinopathy of prematurity is…
Read more

Anti-VEGF drug ranibizumab: A new treatment option against retinopathy of prematurity?

Retinopathy of prematurity (ROP) is an eye disease that only occurs in very premature babies (usually preterm babies born before the 31st week or born with a birthweight below 1250 g). With ROP, unwanted blood vessels grow on the retina in the back of the baby’s eye that can lead to serious eye problems and even blindness. There are two main treatment approaches, laser surgery and anti-VEGF injections. The latter aims at inhibiting VEGF, the growth factor mainly responsible for…
Read more